FLSM
LXEO icon

Frazier Life Sciences Management’s Lexeo Therapeutics LXEO Stock Holding History

Frazier Life Sciences Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.4M Hold
4,424,725
– – 0.65% 26
2025
Q4 		$43.9M Hold
4,424,725
– – 1.18% 21
2025
Q3 		$29.4M Hold
4,424,725
– – 0.88% 25
2025
Q2 		$17.8M Buy
4,424,725
+3,469,210
+363% +$11.4M 0.71% 29
2025
Q1 		$3.32M Hold
955,515
– – 0.15% 45
2024
Q4 		$6.29M Sell
955,515
-295,271
-24% -$2.33M 0.26% 44
2024
Q3 		$11.3M Buy
+1,250,786
New +$14.9M 0.45% 36

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM